Keppra and Malignant melanoma - a phase IV clinical study of FDA data

Summary:

Malignant melanoma is reported as a side effect among people who take Keppra (levetiracetam), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Zolpidem Tartrate, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Malignant melanoma when taking Keppra. It is created by eHealthMe based on reports of 70,297 people who have side effects when taking Keppra from the FDA, and is updated regularly.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.

What is Malignant melanoma?

Malignant melanoma (skin cancer rises from melancytes) is found to be associated with 789 drugs and 741 conditions by eHealthMe. Check the latest studies of Malignant melanoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

70,297 people reported to have side effects when taking Keppra.
Among them, 35 people (0.05%) have Malignant melanoma.

Among these 35 people:

How long have people been on Keppra when they have Malignant melanoma? *

What is the gender of people who have Malignant melanoma when taking Keppra? *

female: 48.57 %
male: 51.43 %

What is the age of people who have Malignant melanoma when taking Keppra? *

What are other drugs people take besides Keppra? *

What are other side effects people have besides Malignant melanoma? *

Fall: 8 people, 22.86%
Malignant Neoplasm Progression (cancer tumour came back): 7 people, 20.00%
General Physical Health Deterioration (weak health status): 6 people, 17.14%
Fainting (loss of consciousness and postural tone): 6 people, 17.14%
Fatigue (feeling of tiredness): 5 people, 14.29%
Hypoaesthesia (reduced sense of touch or sensation): 4 people, 11.43%
Cough: 4 people, 11.43%
Head Injury: 4 people, 11.43%
Stress And Anxiety: 4 people, 11.43%
Oropharyngeal Pain: 4 people, 11.43%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 8 people, 22.86%
Dyslipidaemia (abnormal amount of lipids): 3 people, 8.57%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 5.71%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 5.71%
Primary Immunodeficiency Syndrome: 2 people, 5.71%
Pain: 2 people, 5.71%
Depression: 1 person, 2.86%
Memory Loss: 1 person, 2.86%
Indigestion: 1 person, 2.86%
Glioblastoma Multiforme (most common and deadliest of malignant primary brain tumours in adults): 1 person, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Keppra and have Malignant melanoma?

- Check whether Malignant melanoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keppra:

Keppra (73,504 reports)

Browse all side effects of Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant melanoma:

Malignant melanoma (789 drugs)

Browse all the conditions that are associated with Malignant melanoma:

Malignant melanoma (741 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on levetiracetam (the active ingredients of Keppra) and Keppra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.